BioNTech SE (BNTX) vs Moderna, Inc. (MRNA)

A side-by-side comparison of BioNTech SE and Moderna, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnBNTX vs MRNA

growth of $100 · dividends reinvested · last 7y
BNTX +548.2%MRNA +291.8%BNTX compounded faster
01k2k3kStart $100202120232025$648$392
BNTX MRNA

BNTX vs MRNA: by the numbers

  • BNTX is the larger company ($23.38B vs $22.14B market cap).
  • Both run net losses; BNTX's is the smaller (-44.73% vs -143.55% net margin).
  • MRNA grew revenue faster over the past five years (19.33% vs 2.16% CAGR).

Metrics side by side

Valuation

MetricBNTXMRNA
P/S ratio7.019.88
P/B ratio1.072.97
FCF yield6.49%N/A

Profitability

MetricBNTXMRNA
Gross margin73.26%55.35%
Operating margin-22.63%-153.35%
Net margin-44.73%-143.55%
ROE-6.79%-43.12%
ROIC-3.14%-29.70%

Growth (annualized)

MetricBNTXMRNA
Revenue CAGR (5Y)2.16%19.33%
Total return CAGR (5Y)-20.13%-31.25%

Frequently asked

Which has grown faster, BNTX or MRNA?
Over the past five years, MRNA grew revenue faster — BNTX at a 2.16% CAGR versus MRNA at 19.33%.
How have BNTX and MRNA total returns compared?
Over the past 5 years, BNTX delivered -20.13% and MRNA delivered -31.25% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.